Oncology Precision Therapeutics and Imaging Core

肿瘤学精确治疗和成像核心：项目摘要 肿瘤学精密治疗和成像核心(OPTIC)是Precision公司合并的结果 将治疗能力纳入现有小动物影像共享资源，为目标提供充分 赫伯特·欧文综合癌症翻译肿瘤学的综合和综合服务 中心(HICCC)成员。这些措施包括提供使用成像设备/基础设施、协助 技术程序、监管支持和用户教育。在肯尼斯·奥利弗的领导下， 光学的使命与校园范围的个性化医疗倡议相吻合，并补充了更多 以临床为重点的努力，如HICCC的精确肿瘤学倡议。在当前项目期内 (2014-2019年)，HICCC在光学方面进行了许多重大投资，包括：安装高- 实地9.4T小动物核磁共振，购买新的IVIS Spectrum光学成像仪，并支持推出 精准治疗服务。光学服务分为三大类：(1)产生新的 来自原始患者材料的个性化癌症模型，(2)执行转化性治疗研究 代表用户的小鼠癌症模型，以及(3)小动物成像服务，包括 生物发光/荧光、超声波、微型CT和高场磁共振成像。为了支持这些努力，光学 成立了机构审查委员会(IRB)和机构动物保护和使用委员会(IACUC) 协议，生成了一组IACUC认可的主协议用于映像，这些协议可供轻松参考 用户实验室，并集成了完整的协议流水线，用于生成、表征、使用、 以及对各种各样的肿瘤模型进行成像。作为表征新型癌症的光学管道的一部分 模型，OPTIC与HICCC的其他共享资源密切合作，包括基因组学和High 吞吐量筛选、蛋白质组学和大分子结晶学、分子病理学、数据库和 癌症生物统计学SRS。除了提供基础和高级成像和实验疗法 服务，经验丰富的光学成像和翻译科学家还提供咨询和 对HICCC成员进行实验设计、仪器操作和数据分析方面的培训，这有助于 将先进的实验疗法纳入HICCC成员的研究组合。完毕 在本项目期间，39个HICCC成员利用了光纤的能力，提供了关键数据和 对42项同行评审研究补助金和16份HICCC成员同行评审出版物的见解，其中包括11份 影响因子为&gt；10的期刊上的论文，其中8篇发表在影响因子为&gt；20的期刊上(自然、细胞、自然 医学、癌细胞)。目前，OPTIC支持NIH资助的28笔赠款的研究，其中17笔来自NCI。

ONCOLOGY PRECISION THERAPEUTICS AND IMAGING CORE: PROJECT SUMMARY The Oncology Precision Therapeutics and Imaging Core (OPTIC) is the result of incorporation of precision therapeutic capabilities into the existing Small Animal Imaging Shared Resource the goal of providing fully integrated and comprehensive services in translational oncology for the Herbert Irving Comprehensive Cancer Center (HICCC) members. These include providing access to imaging equipment/infrastructure, assistance in technical procedures, regulatory support, and user education. Under the leadership of Kenneth Olive, PhD the mission of OPTIC dovetails with a campus-wide initiative in personalized medicine, and complements more clinically focused efforts such as the HICCC’s Precision Oncology Initiative. During the current project period (2014-2019), the HICCC has made numerous major investments in OPTIC, including: the installation of a high- field 9.4T small animal MRI, the purchase of a new IVIS Spectrum optical imager, and support for the launch of precision therapeutic services. OPTIC services fall into three broad categories: (1) the generation of new personalized cancer models from primary patient materials, (2) execution of translational therapeutic studies in mouse models of cancer on behalf of users, and (3) small animal imaging services, including bioluminescent/fluorescent, ultrasound, micro CT, and high-field MR imaging. In support of these efforts, OPTIC has established Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) protocols, generated a set of IACUC-approved master protocols for imaging that may be easily referenced by user laboratories, and integrated a complete pipeline of protocols for the generation, characterization, utilization, and imaging of a broad variety of tumor models. As part of the OPTIC pipeline for characterizing novel cancer models, OPTIC collaborates closely with other Shared Resources at the HICCC including: Genomics and High Throughput Screening, Proteomics and Macromolecular Crystallography, Molecular Pathology, DataBase, and Cancer Biostatistics SRs. In addition to providing basic and advanced imaging and experimental therapeutics services, the highly experienced imaging and translational scientists of OPTIC also provide consultation and training to HICCC members in experimental design, instrument operation, and data analysis, which facilitates the incorporation of advanced experimental therapeutics into the research portfolio of HICCC members. Over the current project period, the capabilities of OPTIC were utilized by 39 HICCC members, provided key data and insights for 42 peer-reviewed research grants and 16 HICCC member peer-reviewed publications including 11 papers in journals with impact factor >10 of which 8 were in journals with impact factor >20 (Nature, Cell, Nature Medicine, Cancer Cell). Currently, OPTIC supports research for 28 NIH-funded grants, 17 from NCI.